吉西他滨固定剂量率输注联合替吉奥一线治疗晚期胰腺癌的临床疗效及预后影响因素分析  

Analysis of the clinical efficacy and prognostic factors of gemcitabine fixed-dose rate infusion combined with tigio first-line treatment of advanced pancreatic cancer

作　　者：于文昊 王志鑫[1] 孔繁玉 谢智 任利[1] YU Wenhao;WANG Zhixin;KONG Fanyu;XIE Zhi;REN Li(Department of Hepatobiliary and Pancreatic Surgery,Qinghai University Affiliated Hospital,Xining 810001,Qinghai,China)

机构地区：[1]青海大学附属医院肝胆胰外科,西宁8100010

出　　处：《癌症进展》2021年第10期1031-1034,1042,共5页Oncology Progress

摘　　要：目的探讨吉西他滨固定剂量率输注联合替吉奥(FGS)方案一线治疗晚期胰腺癌的临床疗效,分析晚期胰腺癌患者总生存期(OS)的影响因素。方法依据治疗方法不同将80例晚期胰腺癌患者分为观察组和常规组,每组40例,常规组患者接受吉西他滨单药治疗,观察组患者给予FGS方案一线治疗。比较两组患者的临床疗效、体能状态、生活质量和不良反应发生情况。截至随访结束,比较两组患者的OS,晚期胰腺癌患者OS的影响因素采用Cox风险比例回归模型分析。结果观察组患者的临床疗效明显优于常规组患者,差异有统计学意义(Z=-3.348,P﹤0.01)。治疗后,观察组和常规组患者的卡氏功能状态(KPS)、生命质量(QOL)评分均高于本组治疗前,且观察组患者的KPS、QOL评分均高于常规组患者,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为37.5%,与常规组患者的35.0%比较,差异无统计学意义(P﹥0.05)。Cox风险比例回归模型分析结果显示,TNM分期为Ⅳ期、KPS评分≤70分、合并肝转移和骨转移均是晚期胰腺癌患者OS的独立危险因素(P﹤0.05),采用FGS方案化疗是晚期胰腺癌患者OS的独立保护因素(P﹤0.05)。结论FGS方案一线治疗晚期胰腺癌的临床效果明显,可明显提高患者的生活质量。TNM分期为Ⅳ期、KPS评分≤70分、合并肝转移和骨转移均是晚期胰腺癌患者OS的独立危险因素。Objective To explore the clinical efficacy of fixed-dose rate infusion of gemcitabine combined with tigio(FGS)regimen in the first-line treatment of advanced pancreatic cancer,and analyze the influencing factors of overall survival(OS)in patients with advanced pancreatic cancer.Method According to different treatment methods,80 patients with advanced pancreatic cancer were divided into observation group and routine group,with 40 cases in each group.Patients in the routine group received gemcitabine monotherapy,while patients in the observation group received FGS firstline treatment.The clinical efficacy,physical status,quality of life and adverse reactions of the two groups were compared.By the end of follow-up,the OS of the two groups were compared,and the influencing factors of OS of patients with advanced pancreatic cancer were analyzed by Cox proportional hazards regression model.Result The clinical efficacy of the observation group was significantly better than that of the routine group,and the difference was statistically significant(Z=-3.348,P<0.01).After treatment,the Karnofsky performance status(KPS)and quality of life(QOL)scores of the observation group and the routine group were higher than those before the treatment,and the KPS and QOL scores of the observation group were higher than those of the routine group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 37.5%,compared with 35.0%in the routine group,the difference was not statistically significant(P>0.05).Cox risk proportional regression model analysis showed that TNM stage IV,KPS score≤70 points,combined liver metastasis and bone metastasis were independent risk factors for OS in patients with advanced pancreatic cancer(P<0.05);chemotherapy with FGS regimen is an independent protective factor for OS in patients with advanced pancreatic cancer(P<0.05).Conclusion The FGS regimen has obvious clinical effects in the first-line treatment of advanced pancreatic cancer and

关 键 词：吉西他滨 替吉奥 晚期胰腺癌 临床疗效 生存时间 

分 类 号：R735.9[医药卫生—肿瘤]